Maximising LDL-Cholesterol Reduction: Integrating Inclisiran With Lipid-Lowering Strategies - 02/04/26
Doi : 10.1016/j.hlc.2025.09.022
Francesco Sbrana, MD ⁎ 
, Beatrice Dal Pino, MD
, Beatrice Dal Pino, MD Lipoapheresis Unit and Reference Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
∗ Corresponding author at: Lipoapheresis Unit and Reference Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, 1, 56124 Pisa, Italy Lipoapheresis Unit and Reference Center for Inherited Dyslipidemias Fondazione Toscana Gabriele Monasterio Via Moruzzi 1 Pisa 56124 Italy
Keywords : Alirocumab, Background lipid-lowering treatment, Evolocumab, Inclisiran, LDL-cholesterol target
Il testo completo di questo articolo è disponibile in PDF.
© 2025
Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 35 - N° 4
P. e63-e64 - aprile 2026 Ritorno al numero
Articolo precedente
- From PLATO to Practice: The Challenge of Translating Trial Evidence
- Ashish H. Shah
- Corrigendum to: Abstract 727, Vol 34, Supplement 4, Page S567 (2025) (Abstracts for the 73rd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, 14–17 August 2025) entitled ”Iron Deficiency in Symptomatic Atrial Fibrillation: A Multi-Centre Prospective Observational Study”
- A. Watson, D. Ferreira, A. Chee, A. Balasubramaniam, R. Gleadhill, J. Smiles, S. Jones, K. Cross, A. Albayati, J. Hardy, B. Alabdullah, M. McGee
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?